{"id":34882,"date":"2025-06-06T23:33:41","date_gmt":"2025-06-06T15:33:41","guid":{"rendered":"https:\/\/flcube.com\/?p=34882"},"modified":"2025-06-06T23:33:42","modified_gmt":"2025-06-06T15:33:42","slug":"zelgen-bio-collaborates-with-merck-kgaa-for-rhtsh-promotion-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34882","title":{"rendered":"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China"},"content":{"rendered":"\n

China’s Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266<\/a>) announced a collaboration agreement with Merck KGaA (ETR: MRK<\/a>), appointing the German company as the exclusive market promotion service provider for its recombinant human thyrotropin (rhTSH) for injection in mainland China (excluding Hong Kong, Macau, and Taiwan). Under the agreement, Zelgen Bio will receive an upfront payment of up to RMB 250 million (USD 35 million) and will pay Merck a double-digit percentage of net sales as a market promotion service fee.<\/p>\n\n\n\n

Product Profile<\/strong>
The rhTSH, a biologics drug developed in-house by Zelgen Bio, has a structure identical to the amino acid sequence of endogenous human TSH. It rapidly elevates TSH levels without requiring patients to discontinue thyroid hormone therapy. By binding to the thyrotropin receptor (TSHR) on thyroid follicular cells or thyroid tumor tissue, it stimulates residual thyroid tissue and tumor tissue to enhance iodine uptake and thyroglobulin (Tg) secretion. This improves the sensitivity of postoperative recurrence monitoring and can be used as an adjunctive therapy for radioiodine ablation in differentiated thyroid cancer patients. Similar treatment regimens are widely adopted in the U.S. and European markets.<\/p>\n\n\n\n

Regulatory Status<\/strong>
The drug\u2019s Biologics License Application (BLA) was accepted for review by China’s National Medical Products Administration in June of last year and is currently awaiting regulatory approval.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China’s Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA…<\/p>\n","protected":false},"author":1,"featured_media":34883,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1147,120,905,246],"class_list":["post-34882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-etr-mrk","tag-merck","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"\nZelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA (ETR: MRK), appointing the German company as the exclusive market promotion service provider for its recombinant human thyrotropin (rhTSH) for injection in mainland China (excluding Hong Kong, Macau, and Taiwan). Under the agreement, Zelgen Bio will receive an upfront payment of up to RMB 250 million (USD 35 million) and will pay Merck a double-digit percentage of net sales as a market promotion service fee.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34882\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China\" \/>\n<meta property=\"og:description\" content=\"China's Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA (ETR: MRK), appointing the German company as the exclusive market promotion service provider for its recombinant human thyrotropin (rhTSH) for injection in mainland China (excluding Hong Kong, Macau, and Taiwan). Under the agreement, Zelgen Bio will receive an upfront payment of up to RMB 250 million (USD 35 million) and will pay Merck a double-digit percentage of net sales as a market promotion service fee.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34882\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-06T15:33:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-06T15:33:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0618.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China\",\"datePublished\":\"2025-06-06T15:33:41+00:00\",\"dateModified\":\"2025-06-06T15:33:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0618.webp\",\"keywords\":[\"ETR: MRK\",\"Merck\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34882#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34882\",\"name\":\"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0618.webp\",\"datePublished\":\"2025-06-06T15:33:41+00:00\",\"dateModified\":\"2025-06-06T15:33:42+00:00\",\"description\":\"China's Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA (ETR: MRK), appointing the German company as the exclusive market promotion service provider for its recombinant human thyrotropin (rhTSH) for injection in mainland China (excluding Hong Kong, Macau, and Taiwan). Under the agreement, Zelgen Bio will receive an upfront payment of up to RMB 250 million (USD 35 million) and will pay Merck a double-digit percentage of net sales as a market promotion service fee.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34882\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0618.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0618.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34882#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China - Insight, China's Pharmaceutical Industry","description":"China's Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA (ETR: MRK), appointing the German company as the exclusive market promotion service provider for its recombinant human thyrotropin (rhTSH) for injection in mainland China (excluding Hong Kong, Macau, and Taiwan). Under the agreement, Zelgen Bio will receive an upfront payment of up to RMB 250 million (USD 35 million) and will pay Merck a double-digit percentage of net sales as a market promotion service fee.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34882","og_locale":"en_US","og_type":"article","og_title":"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China","og_description":"China's Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA (ETR: MRK), appointing the German company as the exclusive market promotion service provider for its recombinant human thyrotropin (rhTSH) for injection in mainland China (excluding Hong Kong, Macau, and Taiwan). Under the agreement, Zelgen Bio will receive an upfront payment of up to RMB 250 million (USD 35 million) and will pay Merck a double-digit percentage of net sales as a market promotion service fee.","og_url":"https:\/\/flcube.com\/?p=34882","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-06T15:33:41+00:00","article_modified_time":"2025-06-06T15:33:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0618.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34882#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34882"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China","datePublished":"2025-06-06T15:33:41+00:00","dateModified":"2025-06-06T15:33:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34882"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0618.webp","keywords":["ETR: MRK","Merck","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34882#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34882","url":"https:\/\/flcube.com\/?p=34882","name":"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34882#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0618.webp","datePublished":"2025-06-06T15:33:41+00:00","dateModified":"2025-06-06T15:33:42+00:00","description":"China's Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA (ETR: MRK), appointing the German company as the exclusive market promotion service provider for its recombinant human thyrotropin (rhTSH) for injection in mainland China (excluding Hong Kong, Macau, and Taiwan). Under the agreement, Zelgen Bio will receive an upfront payment of up to RMB 250 million (USD 35 million) and will pay Merck a double-digit percentage of net sales as a market promotion service fee.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34882#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34882"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34882#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0618.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0618.webp","width":1080,"height":608,"caption":"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34882#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0618.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34882"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34882\/revisions"}],"predecessor-version":[{"id":34884,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34882\/revisions\/34884"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34883"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}